Abstract:Highlights • Engineered Lactococcus lactis (FOLactis) could lead to remarkable tumor suppression and exert an abscopal effect. • Delivery system based on thermo-sensitive hydrogel P407 was developed to promote the efficacy and universality of FOLactis. • Peritumoral injection of FO/P407 played the role of artificial lymph island and induced intense antitumor immune response. • FO/P407 inhibited the growth of abdominal metastatic tumors and orthotopic gastric tumors, resulting in extended survival. Engineered bacteria have shown great potential in cancer immunotherapy by dynamically releasing therapeutic payloads and inducing sustained antitumor immune response with the crosstalk of immune cells. In previous studies, FOLactis was designed, which could secret an encoded fusion protein of Fms-related tyrosine kinase 3 ligand and co-stimulator OX40 ligand, leading to remarkable tumor suppression and exerting an abscopal effect by intratumoral injection. However, it is difficult for intratumoral administration of FOLactis in solid tumors with firm texture or high internal pressure. For patients without lesions such as abdominal metastatic tumors and orthotopic gastric tumors, intratumoral injection is not feasible and peritumoral maybe a better choice. Herein, an engineered bacteria delivery system is constructed based on in situ temperature-sensitive poloxamer 407 hydrogels. Peritumoral injection of FOLactis/P407 results in a 5-fold increase in the proportion of activated DC cells and a more than 2-fold increase in the proportion of effective memory T cells (T EM ), playing the role of artificial lymph island. Besides, administration of FOLactis/P407 significantly inhibits the growth of abdominal metastatic tumors and orthotopic gastric tumors, resulting in an extended survival time. Therefore, these findings demonstrate the delivery approach of engineered bacteria based on in situ hydrogel will promote the efficacy and universality of therapeutics. Graphical abstract Download : Download high-res image (294KB) Download : Download full-size image

Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy

An Immunomodulator‐Boosted Lactococcus Lactis Platform For Enhanced In Situ Tumor Vaccine

Injectable thermo-sensitive hydrogel enhances anti-tumor potency of engineered Lactococcus lactis by activating dendritic cells and effective memory T cells

Tumor Eradicated by Combination of Imiquimod and OX40 Agonist for in Situ Vaccination

Abstract 1718: Tumor Eradicated by an Effective in Situ Vaccine Based on a TLR Agonist and an Agonistic Anti-Ox40 Antibody

In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2

Probiotic Engineering and Targeted Sonoimmuno-Therapy Augmented by STING Agonist.

Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

Intra-bone marrow injection with engineered Lactococcus lactis for the treatment of metastatic tumors: Primary report

The Self-Adjuvant Heterocyclic Lipid Nanoparticles Encapsulated with Vaccine and STAT3 Sirna Boost Cancer Immunotherapy Through DLN-targeted and STING Pathway

Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer

Combining iRGD with HuFOLactis enhances antitumor potency by facilitating immune cell infiltration and activation

Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor

Combinatorial leaky probiotic for anticancer immunopotentiation and tumor eradication

In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity

PD-L1 Antibodies-Armed Exosomal Vaccine for Enhanced Cancer Immunotherapy by Simultaneously in Situ Activating T Cells and Blocking PD-1/PD-L1 Axis

Metal-Organic Framework-Based Nanovaccine for Relieving Immunosuppressive Tumors Via Hindering Efferocytosis of Macrophages and Promoting Pyroptosis and Cuproptosis of Cancer Cells.

Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for Cancer Immunotherapy

Microfluidics-enabled fluorinated assembly of EGCG-ligands-siTOX nanoparticles for synergetic tumor cells and exhausted t cells regulation in cancer immunotherapy

Near Infrared Light Activation of an Injectable Whole-Cell Cancer Vaccine for Cancer Immunoprophylaxis and Immunotherapy

In Situ Vaccination with Mitochondria‐Targeting Immunogenic Death Inducer Elicits CD8+ T Cell‐Dependent Antitumor Immunity to Boost Tumor Immunotherapy